Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

Wang, Yu-Jyuan; Lin, Pei‐Ying; Hsieh, Shu‐Ling; Kirankumar, Rajendranath; Lin, Hsin-Yi; Li, Jia-Huei; Chen, Ya-Ting; Wu, Haoming; Hsieh, Shuchen

doi:10.3390/ma14081824

Cited by 15 publications

(15 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SAR values of the nanofluid samples exposed to different AMF strengths are provided in Figure (4h). The SAR values increased considerably with increasing AMF strengths due to the heating loss mechanisms [39], which is also in line with previous research reports such as bare superparamagnetic Fe3O4 [28] and polycaprolactonecoated Fe3O4 [11] and γ-Fe2O3 [40]. Oltolina et al, [41] loaded Dox on biomimetic MNPs mediated with magnetosome proteins (BMNPs) for in vitro and in vivo cancer treatment of mammary carcinoma model, in which hyperthermia improved cancer cell death and controlled drug release.…”

Section: Coated Magnetic Nanoparticles For Combined Therapy Of Hyperthermia and Chemotherapysupporting

confidence: 88%

Magnetic Nanoparticles In Hyperthermia Therapy: A Mini-Review

Yusefi

Shameli

Sukri

2021

JRNN

View full text Add to dashboard Cite

The activation of MNPs for hyperthermia therapy via an external alternating magnetic field is an interesting method in targeted cancer therapy. This mini-review explains new developments and implications of magnetic nanofluids mediated magnetic hyperthermia for their potential use in future clinical settings. The external alternating magnetic field generates heat in the tumor area to eliminate cancer cells. Depending on the tumor type and targeted area, several kinds of MNPs with different coating agents of various morphology and surface charge have been developed. The tunable physiochemical characteristics of MNPs enhance their heating capability. In addition, heating efficiency is strongly associated with the amount of the applied magnetic field and frequency. The great efforts have offered promising preclinical trials of magnetic hyperthermia via MNPs as a smart nanoagent. MNPs are very appropriate to be considered as a heating source in MHT and prospective research in this field will lead to tackle the problems from chemotherapy and introduce promising therapeutic techniques and nanodrug formulations for remotely controlled drug release and anticancer effects. This mini-review aims to pinpoint synthesis and structural analysis of various magnetic nanoparticles examined for magnetic hyperthermia therapy and controlled drug release in cancer treatment.

show abstract

Section: Coated Magnetic Nanoparticles For Combined Therapy Of Hyperthermia and Chemotherapysupporting

confidence: 88%

Magnetic Nanoparticles In Hyperthermia Therapy: A Mini-Review

Yusefi

Shameli

Sukri

2021

JRNN

View full text Add to dashboard Cite

show abstract

“…The drug loading efficiency onto the MNPs carrier is also an important parameter. Drugs can be loaded onto nanoparticles' surfaces using many procedures [39][40][41][42][43][44][45][46]. To evaluate the drug loading potential of MNPs, a chemotherapeutic drug, DOX, with broadspectrum antitumor activity was selected.…”

Section: Anticancer Drug Doxorubicin Loadingmentioning

confidence: 99%

“…Unfortunately, DOX is often associated with multidrug resistance and many side effects [37,38]. One of the prospective possibilities to avoid drug resistance is a synthesis of DOX-loaded nanoparticles [39][40][41][42][43][44][45][46]. Several constructions were studied for DOX loading.…”

Section: Introductionmentioning

confidence: 99%

“…Several constructions were studied for DOX loading. Among them are gold [45], carbonate [40], iron oxide nanoparticles [21,39,41,42,[47][48][49][50][51][52][53][54][55][56][57][58][59], metal-organic frameworks [60], and much more laborious and complex constructions [61][62][63][64]. However, MNPs in the published works demonstrate only a low noncovalent drug loading capacity (µg/mg, DOX/MNP): 11 [55,56], 22 [57], 50 [42,51,58], 91 [54], 110 [41], 120 [65,66], 131 [50], 300 [53].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High Drug Capacity Doxorubicin-Loaded Iron Oxide Nanocomposites for Cancer Therapy

Kovrigina

Chubarov

2022

Magnetochemistry

View full text Add to dashboard Cite

Magnetic nanoparticles (MNPs) have great potential in the drug delivery area. Iron oxide (Fe3O4) MNPs have demonstrated a promising effect due to their ferrimagnetic properties, large surface area, stability, low cost, easy synthesis, and functionalization. Some coating procedures are required to improve stability, biocompatibility, and decrease toxicity for medical applications. Herein, the co-precipitation synthesis of iron oxide MNPs coated with four types of primary surfactants, polyethylene glycol 2000 (PEG 2000), oleic acid (OA), Tween 20 (Tw20), and Tween 80 (Tw80), were investigated. Dynamic light scattering (DLS), ζ-potential, and transmission electron microscopy (TEM) techniques were used for morphology, size, charge, and stability analysis. Methylene blue reactive oxygen species (ROS) detection assay and the toxicity experiment on the lung adenocarcinoma A549 cell line were conducted. Two loading conditions for anticancer drug doxorubicin (DOX) on MNPs were proposed. The first one provides high loading efficiency (~90%) with up to 870 μg/mg (DOX/MNPs) drug capacity. The second is perspective for extremely high capacity 1757 μg/mg with drug wasting (DOX loading efficiency ~24%). For the most perspective MNP_OA and MNP_OA_DOX in cell media, pH 7.4, 5, and 3, the stability experiments are also presented. MNP_OA_DOX shows DOX pH-dependent release in the acidic pH and effective inhibition of A549 cancer cell growth. The IC50 values were calculated as 1.13 ± 0.02 mM in terms of doxorubicin and 0.4 ± 0.03 µg/mL in terms of the amount of the nanoparticles. Considering this, the MNP_OA_DOX nano theranostics agent is a highly potential candidate for cancer treatment.

show abstract

“…Doxorubicin (DOX) is an outstanding anticancer drug [ 57 , 58 , 59 ]. The DOX loading on nanoparticles’ surface serves as a prospective system that reduces side effects and avoids drug resistance problems [ 41 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 ]. Therefore, it is essential to develop new pH-stimuli-responsive DOX-released multifunctional constructions based on MNCs [ 66 , 67 , 68 ].…”

Section: Introductionmentioning

confidence: 99%

pH-Responsible Doxorubicin-Loaded Fe3O4@CaCO3 Nanocomposites for Cancer Treatment

2023

View full text Add to dashboard Cite

A magnetic nanocomposite (MNC) is an integrated nanoplatform that combines a set of functions of two types of materials. A successful combination can give rise to a completely new material with unique physical, chemical, and biological properties. The magnetic core of MNC provides the possibility of magnetic resonance or magnetic particle imaging, magnetic field-influenced targeted delivery, hyperthermia, and other outstanding applications. Recently, MNC gained attention for external magnetic field-guided specific delivery to cancer tissue. Further, drug loading enhancement, construction stability, and biocompatibility improvement may lead to high progress in the area. Herein, the novel method for nanoscale Fe3O4@CaCO3 composites synthesis was proposed. For the procedure, oleic acid-modified Fe3O4 nanoparticles were coated with porous CaCO3 using an ion coprecipitation technique. PEG-2000, Tween 20, and DMEM cell media was successfully used as a stabilization agent and template for Fe3O4@CaCO3 synthesis. Transmission electron microscopy (TEM), Fourier transform infrared (FTIR) spectroscopy, and dynamic light scattering (DLS) data were used for the Fe3O4@CaCO3 MNC’s characterization. To improve the nanocomposite properties, the concentration of the magnetic core was varied, yielding optimal size, polydispersity, and aggregation ability. The resulting Fe3O4@CaCO3 had a size of 135 nm with narrow size distributions, which is suitable for biomedical applications. The stability experiment in various pH, cell media, and fetal bovine serum was also evaluated. The material showed low cytotoxicity and high biocompatibility. An excellent anticancer drug doxorubicin (DOX) loading of up to 1900 µg/mg (DOX/MNC) was demonstrated. The Fe3O4@CaCO3/DOX displayed high stability at neutral pH and efficient acid-responsive drug release. The series of DOX-loaded Fe3O4@CaCO3 MNCs indicated effective inhibition of Hela and MCF-7 cell lines, and the IC 50 values were calculated. Moreover, 1.5 μg of the DOX-loaded Fe3O4@CaCO3 nanocomposite is sufficient to inhibit 50% of Hela cells, which shows a high prospect for cancer treatment. The stability experiments for DOX-loaded Fe3O4@CaCO3 in human serum albumin solution indicated the drug release due to the formation of a protein corona. The presented experiment showed the “pitfalls” of DOX-loaded nanocomposites and provided step-by-step guidance on efficient, smart, anticancer nanoconstruction fabrication. Thus, the Fe3O4@CaCO3 nanoplatform exhibits good performance in the cancer treatment area.

show abstract

Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

Cited by 15 publications

References 36 publications

Magnetic Nanoparticles In Hyperthermia Therapy: A Mini-Review

Magnetic Nanoparticles In Hyperthermia Therapy: A Mini-Review

High Drug Capacity Doxorubicin-Loaded Iron Oxide Nanocomposites for Cancer Therapy

pH-Responsible Doxorubicin-Loaded Fe3O4@CaCO3 Nanocomposites for Cancer Treatment

Contact Info

Product

Resources

About